

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27129/33638A	Serial No. 09/416,828
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Applicant AMMONS, et al.	
		Filing Date 10/12/99	Group <del>1646</del> 1647

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
JR	A1	5,089,274	2/18/92	Marra, et al.	424	534	
	A2	5,171,739	12/15/92	Scott	514	12	
	A3	5,198,541	3/30/93	Elsbach, et al.	435	69.1	
	A4	5,234,912	8/10/93	Marra, et al.	514	21	
	A5	5,308,834	5/3/94	Scott, et al.	514	12	
	A6	5,334,584	8/29/94	Scott, et al.	514	12	
JR	A	5,153,178	10/6/92	Maroko	514	26	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
JR	B1	WO 92/03535	3/5/92	PCT				
	B2	WO 92/09261	6/11/92	PCT				
	B3	WO 93/06228	4/1/93	PCT				
	B4	WO 93/23434	11/25/93	PCT				
	B5	WO 93/23540	11/25/93	PCT				
JR	L	WO 89/12644	12/1989	PCT				

EXAMINER <i>David R. Lewis</i>	DATE CONSIDERED 5/27/11
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

27129/33638A

Serial No.

09/416,828

Applicant

AMMONS, et al.

Filing Date

10/12/99

Group

1646

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

4R	C1	Ammons, et al., "An N-Terminal Fragment Of Bactericidal/Permeability Increasing Protein (rBPI <sub>21</sub> ) Reduces Cardiorespiratory Dysfunction Resulting From Intestinal Ischemia/Reperfusion, <i>Annual Meeting of Professional Scientific Research Scientists, Experimental Biology 94<sup>TM</sup></i> , Anaheim, California, Abstracts 1-3391, Part I, Ischemic Injury, 753 (April 24-28, 1994)
	C2	Bahrami, et al., "Endotoxemia In Rats Subjected To The Haemorrhage: Effects Of Bactericidal/Permeability Increasing Protein (BPI)", <i>Abstract Presented At Vienna International Endotoxin Society Meeting</i> (August, 1992)
	C3	Bahrami, et al., "Bactericidal/Permeability-Increasing Protein (BPI) Reduces Lipopolysaccharide (LPS)-Induced Cytokine Formation And Mortality In Rats," <i>Circulatory Shock</i> , Supplement 1, Abstract 12.25P, Vienna, Austria (May 9-13, 1993)
	C4	Boermeester, et al., "Peri-operative prophylaxis with bactericidal/permeability-increasing protein (rBPI <sub>23</sub> ) prevents early postoperative derangements following partial hepatectomy," <i>Intensive Care Medicine</i> , Volume 20, Supplement 1, Abstract 478 (March, 1994)
	C5	Elsbach, et al., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A <sub>2</sub> from Rabbit Polymorphonuclear Leukocytes," <i>The Journal of Biological Chemistry</i> , Vol. 21, 11000-11009 (November 10, 1979)
	C6	Gathiram, et al., "Changes in Lipopolysaccharide Concentrations in Hepatic Portal and Systemic Arterial Plasma During Intestinal Ischemia in Monkeys," <i>Circulatory Shock</i> , Vol. 27, 103-109 (1989)
	C7	Gazzano-Santoro, et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," <i>Infection and Immunity</i> , Vol. 60, 4754-4761, (November, 1992)
4R	C8	Gray, et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," <i>The Journal of Biological Chemistry</i> , Vol. 264, No. 16, 9505-9509 (June, 1989)

EXAMINER


David Remea

DATE CONSIDERED

5/22/11

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

27129/33638A

Serial No.

09/416,828

Applicant

AMMONS, et al.

Filing Date

10/12/99

Group

1646

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

PR	C9	Mainous, et al., "Bacterial Translocation," <i>Pathophysiology of Shock, Sepsis, and Organ Failure</i> , Springer-Verlag, 265-278 (1993)
	C10	Ooi, et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," <i>J. Exp. Med.</i> , Vol. 174, 649-655 (September, 1991)
	C11	Weiss, et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," <i>Blood</i> , Vol. 69, No. 2, 652-659 (February, 1987)
	C12	Yao, et al., "Effects Of Bactericidal/Permeability Increasing Protein (BPI) Against Haemorrhage-Induced Endotoxemia And Mortality In Rats," <i>Intensive Care Medicine</i> , Volume 20, Supplement 1, Abstract 479 (March, 1994)
	R	Bone, <i>Ann. Internal Med</i> , 115(6): 457-469 (1991)
	S	Glauser et al., <i>Lancet</i> , 338: 732-736 (1991)
	T	Kilbourn et al., <i>J. National Cancer Institute</i> , 84(11): 827-831 (1992)
	U	Natanson et al., <i>Ann. Internal Med.</i> , 120(9): 771-783 (1994)
	R1	<i>The Economist</i> , "Panic in the Petri Dish," pages 61-62 (July 23, 1994)
	S1	Cross et al., <i>Infect. Immun.</i> , 61: 2741-2747 (1993)
	T1	Petros et al., <i>Lancet</i> , 338: 1557-1558 (1991)
	C13	Bahrani et al., "Endotoxemia in Rats Subjected to the Haemorrhage: Effects of Bactericidal/Permeability Increasing Protein (BPI)," <i>Intl. Conf. on Endotoxins</i> , Amsterdam, Aug. 17-20, 1993
	C14	Little et al., "Functional Domains of Recombinant Bactericidal/Permeability Increasing Protein (rBPI <sub>23</sub> )," <i>J. Biol. Chem.</i> , 269:1865-1872 (1994)
PR	C15	Von der Mohlen et al., "Effect of rBPI <sub>23</sub> on Endotoxin-Induced Cytokine Release and Leukocyte Changes in Human Volunteers," <i>Clinical Research Meeting</i> , April 29-May 2 1994

EXAMINER

David Lewis

DATE CONSIDERED

5/27/11

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

27129/33638A

Serial No.

09/416,828

Applicant

AMMONS, et al.

Filing Date

10/12/99

Group

1646

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

AR	C16	Von der Mohlen et al., "Inhibition of Endotoxin-Induced Cytokine Release and Neutrophil Activation in Humans by Use of Recombinant Bactericidal/Permeability-Increasing Protein," <i>J. Infect. Dis.</i> , 172:144-51 (1995)
	C17	Von der Mohlen et al., "Inhibition of Endotoxin-Induced Activation of the Coagulation and Fibrinolytic Pathways Using a Recombinant Endotoxin-Binding Protein (rBPI <sub>23</sub> )," <i>Blood</i> , 85:3437-3443 (1995)
	UU	Novotny et al. "Evidence for lack of importance of oxygen free radicals in Escherichia coli endotoxemia in dogs" <i>Am. J. Physiol.</i> 254 (5 Pt 2): H954-62, (1988) Abstract only provided
	VV	Goto et al., "Adjuvant effects of beta-adrenergic drugs on indomethacin treatment of newborn canine endotoxic shock" <i>J. Ped. Surgery</i> 10:1156-60 (1991) Abstract only provided
	WW	Velkov, "Changes in rabbit cardiac function during fulminant endotoxin shock." <i>Acta Physiol Pharmacol Bulg.</i> 20 (1):19-24 (1994) Abstract only provided
	XX	Bone "Gram-negative sepsis". Background, clinical features, and intervention." <i>Chest</i> , 100 (3) 802-8 (1991), Abstract only provided
PR	YY	Caty et al, "Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury" <i>Annals of Surgery</i> 212 (6):694-700 (1990)

EXAMINER

David Lemo

DATE CONSIDERED

5/22/11

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.